Ironwood Pharmaceuticals Stock Forecast, Price & News

Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

Is Ironwood Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ironwood Pharmaceuticals stock.
View analyst ratings for Ironwood Pharmaceuticals or view top-rated stocks.

How has Ironwood Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Ironwood Pharmaceuticals' stock was trading at $10.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IRWD stock has increased by 4.6% and is now trading at $10.98.
View which stocks have been most impacted by COVID-19.

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 16th 2022.
View our earnings forecast for Ironwood Pharmaceuticals.

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported $0.33 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.02. The biotechnology company earned $103.75 million during the quarter, compared to analysts' expectations of $105.27 million. Ironwood Pharmaceuticals had a trailing twelve-month return on equity of 64.78% and a net margin of 128.30%. The firm's revenue for the quarter was up .3% on a year-over-year basis. During the same quarter last year, the firm earned $0.23 EPS.
View Ironwood Pharmaceuticals' earnings history.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, November, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $390 million-$410 million, compared to the consensus revenue estimate of $408.05 million.

What price target have analysts set for IRWD?

2 equities research analysts have issued 12-month price targets for Ironwood Pharmaceuticals' shares. Their forecasts range from $14.00 to $15.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $14.50 in the next twelve months. This suggests a possible upside of 32.1% from the stock's current price.
View analysts' price targets for Ironwood Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the following people:

• Thomas A. McCourt, President, Chief Executive Officer & Director (LinkedIn Profile)
• Jason Rickard, Chief Financial Officer (LinkedIn Profile)
• Marcel Moulaison, Vice President-Technical Operations
• Michael Shetzline, Chief Medical Officer & Senior Vice President (LinkedIn Profile)
• Cristina Almansa, Head-Clinical Development

What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?

7 employees have rated Ironwood Pharmaceuticals CEO Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among Ironwood Pharmaceuticals' employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Ironwood Pharmaceuticals' key competitors?

Some companies that are related to Ironwood Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Repligen (RGEN), Exact Sciences (EXAS), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of IRWD's competitors.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.66%), LSV Asset Management (4.80%), Camber Capital Management LP (3.38%), Credit Suisse AG (2.86%), Dimensional Fund Advisors LP (1.82%) and Geode Capital Management LLC (1.73%). Company insiders that own Ironwood Pharmaceuticals stock include Alexander J Denner, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Michael Shetzline, Ronald Silver, Thomas A Mccourt, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends for Ironwood Pharmaceuticals.

Which institutional investors are selling Ironwood Pharmaceuticals stock?

IRWD stock was sold by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Renaissance Technologies LLC, Bridger Management LLC, HealthInvest Partners AB, New York State Common Retirement Fund, Islet Management LP, AXA S.A., and Millennium Management LLC. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Jason Rickard, Mark G Currie, Michael Shetzline, Ronald Silver, and Thomas A Mccourt.
View insider buying and selling activity for Ironwood Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was bought by a variety of institutional investors in the last quarter, including LSV Asset Management, Skandinaviska Enskilda Banken AB publ , BlackRock Inc., Foundry Partners LLC, Arrowstreet Capital Limited Partnership, Credit Suisse AG, Two Sigma Advisers LP, and Squarepoint Ops LLC. Company insiders that have bought Ironwood Pharmaceuticals stock in the last two years include Alexander J Denner, and Timothy M O'reilly.
View insider buying and selling activity for Ironwood Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $10.98.

How much money does Ironwood Pharmaceuticals make?

Ironwood Pharmaceuticals has a market capitalization of $1.80 billion and generates $389.52 million in revenue each year. The biotechnology company earns $106.18 million in net income (profit) each year or $3.25 on an earnings per share basis.

How many employees does Ironwood Pharmaceuticals have?

Ironwood Pharmaceuticals employs 232 workers across the globe.

What is Ironwood Pharmaceuticals' official website?

The official website for Ironwood Pharmaceuticals is www.ironwoodpharma.com.

Where are Ironwood Pharmaceuticals' headquarters?

Ironwood Pharmaceuticals is headquartered at 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at (617) 621-7722, via email at [email protected], or via fax at 617-494-0480.